ReviewCureus2022

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review.

Sharina C Macapagal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.